Authors:
GACHON F
CHARRIER S
KWIATKOWSKI F
BESSE G
CURE H
CHASSAGNE J
FERRIERE JP
PENAULTLLORCA F
DAUPLAT J
CHOLLET P
Citation: F. Gachon et al., EXPRESSION OF CYTOSOLIC THYMIDINE KINASE IN THE PROLIFERATIVE BREAST-CARCINOMA AFTER PRIMARY CHEMOTHERAPY - THERAPEUTIC INDICATION, European journal of cancer, 34, 1998, pp. 469-469
Authors:
CURE H
VANPRAAGH I
CHARRIER S
KWIATKOWSKI F
FERRIERE JP
CHOLLET P
Citation: H. Cure et al., PHASE-I OF DOXORUBICIN AND IFOSFAMIDE ASSOCIATION FOR FIRST LINE ADVANCED BREAST-CANCER (ABC), Annals of oncology, 9, 1998, pp. 115-115
Authors:
FERRIERE JP
ASSIER I
CURE H
CHARRIER S
KWIATKOWSKI F
ACHARD JL
DAUPLAT J
CHOLLET P
Citation: Jp. Ferriere et al., PRIMARY CHEMOTHERAPY IN BREAST-CANCER - CORRELATION BETWEEN TUMOR RESPONSE AND PATIENT OUTCOME, American journal of clinical oncology, 21(2), 1998, pp. 117-120
Authors:
CHARRIER S
CHASSAGNE J
CURE H
BAY JO
COMMUNAL Y
PORTEFAIX G
FERRIERE JP
BETAIL G
PLAGNE R
CHOLLET P
Citation: S. Charrier et al., MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS AFTER INDUCTION CHEMOTHERAPY RUBICIN-VINORELBINE-CYCLOPHOSPHAMIDE-FLUOROURACIL) AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN BREAST-CANCER, Bone marrow transplantation, 22(9), 1998, pp. 845-851
Authors:
CHARRIER S
FERRIERE JP
KWIATKOWSKI F
CURE H
VANPRAAGH I
FEILLEL V
ASSIER I
BAY JO
DAUPLAT J
CHOLLET P
Citation: S. Charrier et al., OPTIMAL DURATION OF NEOADJUVANT CHEMOTHERAPY - 3 OR 4 VERSUS 6 CYCLESIN 3 SCHEMES FOR OPERABLE BREAST-CANCER, European journal of cancer, 33, 1997, pp. 360-360
Authors:
CHOLLET P
CHARRIER S
BRAIN E
CURE H
VANPRAAGH I
FEILLEL V
DELATOUR M
DAUPLAT J
MISSET JL
FERRIERE JP
Citation: P. Chollet et al., CLINICAL AND PATHOLOGICAL RESPONSE TO PRIMARY CHEMOTHERAPY IN OPERABLE BREAST-CANCER, European journal of cancer, 33(6), 1997, pp. 862-866
Authors:
FERRIERE JP
CHARRIER S
CURE H
KWIATKOWSKI F
COURTADON M
BELEMBAOGO E
DELATOUR M
ACHARD JL
DAUPLAT J
CHOLLET P
Citation: Jp. Ferriere et al., ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN-CONTAINING REGIMEN FOR 326 STAGE-II BREAST CANCERS - 15-YEAR RESULTS, American journal of clinical oncology, 20(3), 1997, pp. 219-225
Authors:
VANPRAGGH I
FERRIERE JP
CURE H
FEILLEL V
LEBOUEDEC G
DELATOUR M
ROLHION C
CHARRIER S
ASSIER I
MISSET JL
DAUPLAT J
CHOLLET P
Citation: I. Vanpraggh et al., COMPARISON OF 3 NEOADJUVANT CHEMOTHERAPY REGIMENS FOR OPERABLE BREAST-CANCER, European journal of cancer, 31A, 1995, pp. 53-53
Authors:
FLEURY J
TORTOCHAUX J
LEGROS M
CURE H
KWIATKOWSKI F
FERRIERE JP
TRAVADE P
DIONET C
GAILLARD G
CHASSAGNE J
BIGNON YJ
VANPRAAGH I
BELEMBAOGO E
CHOLLET P
PLAGNE R
Citation: J. Fleury et al., PRONOSTIC VALUE OF BETA-2-MICROGLOBULIN I N YOUNG-ADULTS WITH HODGKINS-DISEASE, Bulletin du cancer, 81(7), 1994, pp. 625-631
Authors:
ATTIASOBOL J
FERRIERE JP
CURE H
KWIATKOWSKI F
ACHARD JL
VERRELLE P
FEILLEL V
DELATOUR M
LAFAYE C
DELOCHE C
DAUPLAT J
DOLY A
ROZAN R
CHOLLET P
Citation: J. Attiasobol et al., TREATMENT RESULTS, SURVIVAL AND PROGNOSTIC FACTORS IN 109 INFLAMMATORY BREAST CANCERS - UNIVARIATE AND MULTIVARIATE-ANALYSIS, European journal of cancer, 29A(8), 1993, pp. 1081-1088